Tag: Eligible

Latest News

 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

Newsemia
LONDON–(BUSINESS WIRE)–Vertex announced reimbursement of SYMDEKO for eligible patients ages 12 and older, and ORKAMBI for children ages 2 to 5 in Australia. Source link...
Cardiology

[Proportion of patients with heart failure in a specialized clinic eligible for novel therapies].

Newsemia
Related Articles [Proportion of patients with heart failure in a specialized clinic eligible for novel therapies]. Rev Med Chil. 2019 Mar;147(3):330-333 Authors: Rossel V, Duarte...
Latest News

Study Investigating Darzalex®▼ (daratumumab) Shows Improved Depth of Response and Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant

Newsemia
BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CASSIOPEIA (MMY3006, NCT02541383) study, an Intergroupe Francophone du...
Biology

Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection

Newsemia
This article was originally published at https://www.drugpatentwatch.com/blog/why-follow-on-pharmaceutical-innovations-should-be-eligible-for-patent-protection/ This article was originally published by Christopher M. Holman in Intellectual Property Watch under a Creative Commons Attribution-NonCommercial-ShareAlike...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy